



AIDS Vaccines: The Next Frontiers | 20

AVAC Report | 06



ACKNOWLEDGEMENTS

AVAC gratefully acknowledges many friends and colleagues in government, industry, academia and the advocacy community for their expertise and advice as we researched and prepared this report.

This Report was written and edited by AVAC staff and board, and coordinated by Emily Bass.

We especially thank Susan Buchbinder, Ward Cates, José Esparza, Pat Fast, Mark Feinberg, Don Francis, Michelle Galloway, Christian Gladel, Isaac Hammond-Paul, Cate Hankins, Mary Frances Hansford, Barton Haynes, Peggy Johnston, Patricia Kahn, Beryl Koblin, Wayne Koff, Katharine Kripke, Michelle Lally, Heidi Lasher, Donna Lomangino, Nicole Lynch, Adel Mahmoud, Siobhan Malone, Kay Marshall, Betsy Martin, John Mascola, Ben Masse, Camille Massey, Margaret McCluskey, Elizabeth McGrory, Nelson Michael, Gary Nabel, Maggie Nicoletti, Lynn Paxton, Gita Ramjee, Helen Rees, Mike Robertson, Jeff Safrin, Sarah Schlesinger, Steve Self, Stuart Shapiro, Melissa Simek, Stephanie Skoler, Jim Tartaglia, Margaret Wecker and Peg Willingham.

AVAC is dedicated to accelerating the ethical development and global delivery of vaccines for AIDS. AVAC does not accept funding from government or the pharmaceutical industry. This publication and AVAC's continuous policy, advocacy, and outreach work is made possible by the dedicated labor of AVAC advocates and support from the Blum-Kovler Foundation, Broadway Cares/Equity Fights AIDS, the Ford Foundation, the Bill & Melinda Gates Foundation, the International AIDS Vaccine Initiative, the Overbrook Foundation, Until There's a Cure Foundation, UNAIDS, the WHO-UNAIDS HIV Vaccine Initiative, and many generous individuals who have become AVAC Members.

TABLE OF CONTENTS

In Memoriam: Beth Waters Finston	4
Letter from the Board President and Executive Director	5
Box 1: What We'll Be Looking for This Time, Next Year	6
CHAPTER 01	
SCENARIO 1:	
Dateline: 2009	
Location: A major European city	9
AIDS Vaccine Science, Strategy and Action:	
The State of the Field, the Stakes for the Future	10
Box 2: Update on the Global HIV Vaccine Enterprise	11
Figure 1: Understanding the Cosmology of the Global HIV Vaccine Enterprise	14
Box 3: The Fundamental Questions that are Still Unanswered	16
Figure 2: Non-Commercial Funding Allocations for Preventative HIV Vaccine R&D by Category in 2005	17
Figure 3: Sources of Global Funding for HIV Vaccine R&D in 2005	18
Box 4: Adding It All Up: Funding for HIV Vaccine Development, 2000 to 2005	19
Table 1: Annual Investments in Preventive HIV Vaccine R&D between 2000 and 2005	20
Table 2: Trials of HIV/AIDS Vaccines Worldwide	22
CHAPTER 02	
SCENARIO 2:	
Dateline: 2011	
Location: Kiev, Ukraine	27
Reports from the Frontlines:	
Learning from Last Year's Clinical Trials	28
Figure 4: Countries Conducting AIDS Vaccine Trials	29
Box 5: What Would Make Multi-functional Sites a Reality?	
Perspectives from South Africa	30
Figure 5: Estimated Number of Adults and Children Newly Infected with HIV, 2005	32
CHAPTER 03	
SCENARIO 3:	
Dateline: 2010	
Location: Kamwokya Trading Center, Kampala, Uganda	37
The Emerging Adolescent Agenda:	
HPV Vaccine, AIDS Prevention Research, and the New Opportunities for Reaching the Young People of the World	38
Table 3: HPV Vaccine and HIV Vaccines: How Do They Compare?	40
Box 6: Telling the Truth to Save Lives: The Ongoing Fight for Evidence-based Prevention	43
CHAPTER 04	
SCENARIO 4:	
Dateline: 2013	
Location: Sub-Saharan Africa	45
AIDS Prevention Evolves (Again):	
Why we are on the verge of an era of new complexity?	46
Table 4: Trials of New Prevention Options Worldwide	47
Table 5: Considerations for use of a placebo versus an active control	49
Table 6: Present and Future Prevention Trial Designs	50
Figure 6: Research That Could Redefine Prevention: Timeline of Anticipated Results	52